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Abstract: Psoriasis is the skin disease that most frequently affects the nails. Depending on 
the very nail structure involved, different clinical nail alterations can be observed. Irritation 
of the apical matrix results in psoriatic pits, mid-matrix involvement may cause leukonychia, 
whole matrix affection may lead to red lunulae or severe nail dystrophy, nail bed involvement 
may cause salmon spots, subungual hyperkeratosis, and splinter hemorrhages, and psoriasis of 
the distal nail bed and hyponychium causes onycholysis whereas that of the proximal nail fold 
causes psoriatic paronychia. The more extensive the involvement, the more severe is the nail 
destruction. Pustular psoriasis may be seen as yellow spots under the nail or, in case of acroder-
matitis continua suppurativa, as an insidious progressive loss of the nail organ. Nail psoriasis 
has a severe impact on quality of life and may interfere with professional and other activities. 
Management includes patient counseling, avoidance of stress and strain to the nail apparatus, 
and different types of treatment. Topical therapy may be tried but is rarely sufficiently efficient. 
Perilesional injections with corticosteroids and methotrexate are often beneficial but may be 
painful and cannot be applied to many nails. All systemic treatments clearing widespread skin 
lesions usually also clear the nail lesions. Recently, biologicals were introduced into nail psoriasis 
treatment and found to be very effective. However, their use is restricted to severe cases due to 
high cost and potential systemic adverse effects.
Keywords: nail psoriasis, etiology, pathology, quality of life, impact, treatment
Introduction
Psoriasis is a chronic inflammatory disease with a strong genetic background but highly 
influenced by environmental factors. Its prevalence is ~1–2% of the world population 
with considerable differences among regions and individuals with different skin types. 
It is the skin disease that most frequently affects the nail. At the time of consultation, 
roughly one half of the patients suffer from nail changes. Over lifetime, up to 90% of 
all psoriatics will have had nail alterations. The prevalence of nail psoriasis is even 
higher in psoriatic arthritis.1 Nail lesions often appear around 10 years later than 
skin lesions, which may in part be the reason for nail psoriasis being observed less 
frequently in children. In general, cutaneous psoriasis is more severe in individuals 
with nail involvement.
Etiology and pathogenesis
Neither gender nor race predilection appears to exist. There is no association of HLA-
C0602 with nail and joint involvement, but nail psoriasis is often associated with an 
inflammation at the insertion points of tendons and ligaments giving rise to enthesitis. 
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Thus, the nail lesions were believed to represent an abnormal 
response to tissue stressing of the integrated nail-joint appara-
tus, rather than being due to autoimmunity. The nail and joint 
disease may be linked to tissue-specific factors, including 
tissue biomechanical stressing and microtrauma, that lead to 
activation of aberrant innate immune responses.2 However, a 
case of skin and nail psoriasis definitely disappearing after 
allogeneic bone marrow transplantation is more in favor of 
predominant immunogenetic factors.3
Clinical characteristics of nail 
psoriasis
Psoriasis causes a variety of both specific as well as ambigu-
ous nail lesions. Fingernails are more frequently affected than 
toe nails, probably because they grow faster. Particularly, for 
scientific purposes, nail psoriasis is often divided into matrix 
and nail bed involvement or both, which is also reflected in 
many trials differentiating the response into general, more on 
matrix or nail bed psoriasis. Pits are the most characteristic 
and most frequent signs and are seen as small, sharply delim-
ited depressions in the nail surface. They are of remarkably 
even size and depth. Their distribution may be haphazard or 
they may sometimes be arranged in parallel transverse or 
short longitudinal lines. They are the result of tiny psoriatic 
foci in the apical matrix producing parakeratosis, which 
breaks off when it grows out from under the proximal nail 
fold then leaving these depressions. Sometimes, the para-
keratosis remains and is seen as an ivory-colored spot in the 
proximal half of the nail plate. Pits may be single, which is 
not yet psoriasis specific, or multiple. Ten pits in one nail or 
>50 pits on all nails are regarded as proof of psoriasis. Red 
spots in the lunula usually represent a very active psoriasis 
lesion with dilatation of the capillaries and thinning of the 
suprapapillary plate. Red or mottled lunulae are due to the 
dilatation of matrix blood vessels.4
Total matrix affection results in complete nail destruction 
with crumbling of the plate, whereas leukonychia is seen 
when the mid- to distal matrix is affected and parakeratotic 
cells are incorporated into the nail plate making it optically 
opaque. In most cases, psoriatic leukonychia is an ill-defined 
white transverse band. Splinter hemorrhages are very narrow, 
some millimeters long reddish-darkbrown to black streaks. 
They are analogous to Auspitz’s phenomenon of the skin 
and either due to hemorrhage from the dilated capillaries 
in the nail bed or due to blood clots in these longitudinally 
arranged small vessels. Salmon or oil spots are very frequent 
and represent psoriatic plaques in the most distal matrix and 
the nail bed. This area looks like paper on which a drop of oil 
has fallen: a yellowish-brownish spot with a red margin shines 
through the plate because the psoriatic squames compressed 
under the nail are imbibed with serum. When a salmon spot 
reaches the hyponychium, the parakeratosis breaks out and 
psoriatic onycholysis develops. This typically has a reddish 
proximal margin differentiating it from most other causes of 
onycholysis, such as onychomycosis. Subungual hyperpara-
keratosis may be thick and then no oil drop phenomenon is 
seen. The hyperkeratosis may be very marked and at times 
so extreme as to resemble pachyonychia congenita. Psoriasis 
affecting the dorsal as well as the ventral surface of the proxi-
mal nail fold results in swelling and rounding of its free edge. 
This leads to a spontaneous loss of the cuticle characterizing 
the pattern of chronic paronychia.
As mentioned earlier, psoriatic arthritis is very frequently 
associated with severe nail involvement and psoriatic paro-
nychia, complete nail destruction, and swelling of the distal 
interphalangeal joint. This has a serious negative influence 
on the quality of life.
In contrast, psoriatic pachydermoperiostosis is closely 
related to psoriatic arthritis but usually without obvious nail 
changes. Mainly the big toe is considerably swollen and 
often painful.
Three different forms of pustular psoriasis are differenti-
ated. Nail changes are seen in all of them. The nail changes in 
the palmar plantar pustular psoriasis of Barber–Königsbeck 
are similar to the common type of psoriasis, but the surface 
defects may be larger and are called elkonyxis. Yellow sub-
ungual spots represent large Munro’s abscesses. Subungual 
abscesses are frequent in the generalized pustular psoriasis 
of von Zumbusch. Acrodermatitis continua suppurativa of 
Hallopeau is the most notorious form of pustular psoriasis of 
the nails. It often begins with one single digit where the skin 
of the distal phalanx turns red and develops some pustules 
migrating under the nail and causing nail dystrophy. With 
time, the entire nail unit may disappear leaving a red smooth 
digit tip until the disease slowly wanes off. Less frequently, 
acrodermatitis continua suppurativa may initially involve 
several fingers and toes and run a rapid and severe course. 
Recently, a mutation in the interleukin 36 receptor antagonist 
gene leading to a defect in interleukin 36 antagonist was 
identified in generalized pustular psoriasis and acrodermatitis 
continua suppurativa supporting the view that it belongs to 
the autoinflammatory diseases group.5,6 Pustulosis palmo-
plantaris is histopathologically and genetically different and 
rarely affects the periungual skin.7
Reiter’s disease is also known as reactive arthritis. It is 
a systemic condition with characteristic joint, mucosal, eye, 
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genito-urinary, skin, and nail changes. The latter are very 
similar to pustular psoriasis. However, they often have a more 
brownish tint due to a higher content of erythrocytes in the 
pustules. Histopathology with extensive spongiform pustules 
is virtually identical to pustular psoriasis.8
Nail psoriasis in children
Psoriasis may occur at any age. Although rare, it was also 
observed in the newborn. Erythrodermic psoriasis in children 
usually shows ungual involvement with nail dystrophy and 
marked subungual hyperkeratosis similar to pityriasis rubra 
pilaris. Even pustular psoriasis and psoriatic arthritis were 
observed in children.6
Diagnosis of nail psoriasis
In most cases, nail psoriasis follows cutaneous psoriasis and 
is therefore easy to diagnose. However, ~5% of nail pso-
riasis occurs isolated and may pose diagnostic challenges. 
This is particularly the case when even the nail alterations 
are atypical such as a single nail in a child or of a toe, 
isolated nail bed psoriasis without pits and salmon spots. 
Histopathology is usually diagnostic, provided the biopsy is 
sufficient, which is, unfortunately, often not the case. It has 
to be remembered that matrix lesions cause changes of the 
nail plate and those of the nail bed are seen under the nail 
plate. The biopsy has to be taken slightly more proximal 
than anticipated and must include enough subungual soft 
tissue. In contrast, nail clippings are diagnostic for the most 
important differential diagnosis, the various onychomycosis 
forms, and sometimes give a strong hint at nail psoriasis. 
Furthermore, nail psoriasis exhibits some features not com-
monly seen in cutaneous lesions.1 Dermatoscopy makes 
the clinical signs more obvious and helps in the diagnosis. 
Videodermatoscopy allows higher magnifications than the 
usual hand-held dermatoscopes. Capillaroscopy shows the 
dilated tortuous capillaries of the proximal nail fold. This 
is even better visible in laser confocal microscopy. The 
features of high-frequency ultrasound are less reliable but 
may be of help for the very experienced. Optical coherence 
microscopy uses a similar principle but has a much higher 
resolution.
Differential diagnosis
In most cases, nail psoriasis is diagnosed on clinical grounds.8 
Skin lesions elsewhere with one or several psoriatic nail 
features suggest the correct diagnosis. With a good biopsy, 
histopathology is usually pathognomonic and helps to delin-
eate nail psoriasis from other conditions, particularly onycho-
mycosis. The clinical diagnosis of pustular psoriasis is made 
on the basis of red skin areas with a rim of small pustules. 
Reiter’s disease requires additional laboratory examinations.1
Onychomycosis is said to be the most frequent nail dis-
ease. It has many features in common with nail psoriasis, 
both clinically and histopathologically (Table 1).1
Another important differential diagnosis is the asym-
metric gait nail unit syndrome seen mainly in the big toenail 
as an onycholysis without further criteria of nail psoriasis or 
onychomycosis.9 Furthermore, nonspecific nail dystrophy, 
particularly of toenails, is very common in the elderly, in 
subjects with peripheral arterial disease, chronic venous 
stasis, after trauma to the leg, in peripheral neuropathy, and 
in some dermatoses such as eczema, nail lichen planus, 
Darier’s disease, Hailey-Hailey disease, alopecia areata, and 
many drugs.1,8
Table 1 Differential diagnosis of nail psoriasis and onychomycosis
 Psoriasis Onychomycosis
Frequency High, commonest dermatosis with nail involvement Very high: up to 30–40% of all nail disorders
Course Chronic, often recurrent Chronic, often progressive
Symptoms Usually cosmetically and functionally embarrassing Embarrassing, sometimes pain
Signs Variable depending on nail structure involved Variable, depending on severity and type of onychomycosis as 
well as pathogenic agent
Pits Very common, regular in size and shape Rare, irregular
Onycholysis Common Common
Discoloration None to yellow Yellow to brown
Spores and hyphae Rarely spores Very frequent
Transverse furrows Rare Rare
Skin lesions elsewhere Very common Often tinea pedum/manuum
Trauma May be induced by Köbner phenomenon Important predisposing factor
Heredity Strong hereditary component, particularly in juvenile 
onset psoriasis
Autosomal dominant susceptibility to develop onychomycosis
Note: Copyright © 2009. Haneke E. Adapted from Haneke E. Non infectious inflammatory disorders of the nail apparatus. J Dtsch Dermatol Ges. 2009;7:787–797.10 Data 
from Haneke E.1
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Grading and assessment of nail 
psoriasis
Reliable repeatable specific validated severity and outcome 
measures are necessary to evaluate a disease and its response 
to a specific treatment.11 This was missing in nail psoriasis 
until the nail psoriasis severity index (NAPSI), target NAPSI, 
and its many variants were established.12 NAPSI is calculated 
by dividing each nail into four quadrants. Each quadrant is 
evaluated for the presence of psoriasis manifestations of 
the nail matrix, such as pitting, leukonychia, red spots in 
the lunula, and nail plate crumbling, as well as of the nail 
bed, such as oil-drop phenomenon, onycholysis, subungual 
hyperkeratosis, and splinter hemorrhages. If any of these 
signs is present in all four quadrants, a score of 4 is given. 
A score of 0 represents no signs in any quadrant. Each nail 
is evaluated for a matrix and a nail bed score of 0–4. They 
are combined to yield a maximal score of 0–8 for each nail. 
All nails may be evaluated, with the total NAPSI score being 
the sum of the scores, up to 80 if only fingers are considered, 
or up to 160 if fingers plus toes are included.12 If only the 
most seriously affected nail is evaluated, it is called target 
NAPSI; this is often done to assess the effects of a therapeutic 
regimen.11 Many therapeutic studies use (target) NAPSI-50, 
NAPSI-75, and NAPSI-90 to indicate the percentage of 
patients that reach a (target) NAPSI improvement of 50, 75, 
or 90%, respectively. The NAPSI has some disadvantages, 
such as being too time-consuming to be used in clinical 
practice, and that the NAPSI scores often do not correspond 
with the clinical severity of nail psoriasis.13 A new scoring 
system, the N-NAIL, overcomes many of these limitations, 
but it has yet to prove its clinical practicability.13 The use of 
many different scoring systems, major differences in study 
design, inclusion criteria, and follow-up make it difficult if 
not impossible to compare the results of most nail psoriasis 
trials.11 In addition, subjective and objective patient factors 
such as quality of life, satisfaction with treatment ease and 
outcome, adverse effects and not the least practicability, and 
cost of treatment are important factors.11 Such an evalua-
tion and assessment tool for nail psoriasis has recently been 
published under the term of nail assessment in psoriasis and 
psoriatic arthritis.14
Associations
Psoriasis is a frequent skin disease. In the last decades, a 
metabolic syndrome associated with psoriasis has been 
described; however, this is not of particular importance for 
ungual psoriasis except in psoriatic arthritis. Associations 
and co-occurrence with other skin disorders involving the 
nail are rather common. The most important differential 
diagnosis is onychomycosis. Both conditions may look very 
similar. A psoriatic nail may be colonized with pathogenic 
fungi, and a true infection of the psoriatic nail is not infre-
quent (Table 1).1,15
Impact on quality of life
Nail psoriasis has a profound negative influence on all aspects 
of quality of life as well as on daily, sports, and professional 
activities.16–20 Women try to hide their nails and cover them 
with nail lacquer; although common nail varnishes are not 
harmful, artificial nails, particularly when long, increase 
the mechanical stress and strain to the nail plate – nail bed 
attachment acting as a Köbner phenomenon and worsening 
nail psoriasis. Similarly, professional activities with particu-
lar use of the fingers may have a deteriorating effect on the 
disease. Matrix involvement scores higher than pure nail bed 
affection as it results in more obvious nail plate damage.19
Course
Nail psoriasis is chronic but often improves and worsens 
without known reasons (Figures 1–4). Trauma may play an 
important role in the exacerbation of nail psoriasis. There 
may be periods without any nail alterations.1,8,10
Management of nail psoriasis
Management of the disease includes patient education, 
avoidance of trauma to the nails, and different therapeutic 
approaches with physical and pharmaceutical procedures 
and agents.
Patient counseling includes education on the nature of 
psoriasis, how life may be influenced by nail involvement, 
about the specific problems of treatment, that nail psoriasis 
is not due to an allergy or an “unhealthy” diet and thus is not 
treatable with particular foods. However, smoking increases 
the risk of psoriasis and obesity and alcohol use are associated 
Figure 1 The thumbs of the patient mainly show nail bed involvement with 
subungual hyperkeratosis, salmon spot, and onycholysis.
Notes: (A) Before treatment (September 2011). (B) After 3 months of topical 
treatment with calcipotriol plus betamethoasone dipropionate ointment and 
clobetasol solution under the nails: the right thumb shows some improvement and 
the left thum nail has worsened (December 2011).
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with a higher risk for psoriasis. It is important to avoid trauma 
to the nail unit that will inevitably exacerbate the condition 
or induce recurrences. Manicure and nail cleaning have to 
be performed cautiously without further traumatizing the 
hyponychium and attachment of the nail to the nail bed. It is 
helpful to explain that genes are the most important etiologi-
cal factors and that the skin and nail lesions are amenable to 
treatment but that the genes cannot be corrected. Many genes 
contribute to the psoriatic personality, which may explain the 
enormous variability of the clinical features including the 
response to treatment. Particularly, chronic repeated trauma 
is thought to be an aggravating factor. The development of 
pits may be the result of microtraumata to the enthesis of the 
extensor tendon and the dorsal aponeurosis of the distal inter-
phalangeal joint.2 They may be masked using nail varnish.
All nail psoriasis treatments require a long time, as the 
nail is a slow-growing cutaneous appendage. The effect of any 
treatment can usually not be evaluated before 3–6 months, 
and it may take a year or longer to reach the maximum 
improvement achievable with a given therapy. Pretreatment 
photographs are highly recommended and should be repeated 
at all follow-up visits to show the therapeutic result to the 
patients. Concomitant onychomycosis may prevent clinical 
cure, and it is a must to exclude fungal infection when start-
ing nail psoriasis therapy; a single remaining altered nail 
during an otherwise efficacious therapy may be a hint at a 
concomitant mycotic infection.1,21
Many different therapeutic measures are available. Their 
choice depends on various factors such as severity of nail 
involvement and its impact on quality of life, associated skin 
lesions, psoriatic arthritis, comorbidities, profession, age, 
patient preferences, potential risks, and not the least costs 
and their reimbursement.
Nail psoriasis is very recalcitrant to almost all topical 
treatments, whereas systemic therapies clearing the skin 
are usually effective also in nail psoriasis.22 The problem of 
all topical drugs is their limited penetration to the diseased 
tissue: through all layers of the proximal nail fold with the 
underlying nail in matrix lesions, through the nail plate, and 
subungual hyperkeratosis in nail bed psoriasis. Hence, pits, 
though often being rather inconspicuous, are the most resis-
tant to treatment. Nevertheless, a 3-month trial of a potent 
antipsoriatic topical preparation is warranted (Figure 1). The 
less nail is left the easier the penetration of the drug to the 
very psoriatic lesion is. Clipping the onycholytic nail over 
the nail bed is essential to reach nail bed psoriasis. Thinning 
the nail by filing or grinding, or drilling holes into the nail 
plate with mechanical burrs23 or with ablative lasers, is often 
used to enhance nail penetration.24
Corticosteroids are often used in nail psoriasis. They have 
to be class IV (high potency) and applied once or twice a day 
on the proximal nail fold in case of matrix and on the nail 
plate in nail bed affection. Although probably still the most 
commonly used drugs, corticosteroids were rarely tested 
in controlled studies. Both clobetasol and betamethasone 
dipropionate were tested in clinical trials and showed compa-
rable results11 concerning pitting, salmon patches, subungual 
hyperkeratosis, and onycholysis.25,26 All high-potency steroids 
carry the risk of skin atrophy when used on the proximal nail 
fold, often associated with hypopigmentation. Whether or 
not using them for 4–5 days a week as a “pulse” treatment is 
Figure 2 Further development of the nail psoriasis.
Notes: (A) After continued topical treatment (March 2012). (B) After repeated 
perilesional injections of triamcinolone acetonide crystal suspension (10 mg/mL), a 
marked improvement is seen (June 2012).
Figure 3 As topical and injection treatments are insufficient and inconvenient, 
systemic methotrexate is instituted.
Notes: (A) Further improvement of the left thumb nail after 2 months of 
methotrexate (September 2012). (B) Despite continuous methotrexate therapy, 
the left thumb nail worsened again (July 2013).
Figure 4 There is residual nail bed psoriasis under methotrexate therapy. Finally, a 
biological treatment is instituted.
Notes: (A) Slight distal onycholysis and subungual hyperkeratosis (November 
2013). (B) Six weeks after the beginning of adalimumab therapy, the patient has 20 
clear nails for the first time since >25 years.
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equally effective and reduces this risk remains to be proven. 
Clobetasol 8% was tested as a nail lacquer with good results 
depending of the duration of the treatment.27
Perilesional injections are another type of local treat-
ment. This increases the concentration of the drug at the 
site of disease while minimizing the dose for the whole 
organism. Perilesional injection of corticosteroids is by far 
the most often performed (Figure 2), either by injection with 
a needle or by high air-pressure devices.28 Injection with a 
30 G needle and using some distraction techniques such as 
vibration and pressure around the area to be injected make 
the procedure tolerable although some patients prefer the 
needle-less technique. Apparently, the efficacy of different 
high-pressure injectors varies considerably (O Correia, Inst 
CUF, personal communication, 2014). We inject 0.1 mL of 
a triamcinolone acetonide suspension (10 mg/mL) into both 
sides of the proximal nail fold; injection into or under the nail 
bed is extremely painful and requires prior anesthesia.29,30 The 
injections are repeated on a monthly basis for 6 months and, 
then, followed by every 6 weeks and later every other months. 
However, not all patients tolerate the injections. Matrix and 
nail bed signs of psoriasis respond slightly differently with 
salmon spots and subungual hyperkeratosis usually show-
ing the best effect. Adverse effects are not uncommon with 
subungual hematoma and temporary nail deformation being 
relatively frequent29,30 and the disappearing digit, atrophy of 
the terminal phalanx bone, and rupture of the extensor tendon 
being the most serious ones.31–34 Epidermoid inclusion cysts 
were observed after jet injections necessitating amputation.35
The combination of the vitamin D
3
 derivate calcipotriol 
and a potent corticosteroid, such as betamethasone dipro-
pionate, has shown good results;26,27 personal experience 
has shown that twice or even thrice daily application may be 
worth trying. Another vitamin D derivative, such as tacalcitol, 
was used alternatively with 8% clobetasol nail lacquer.33
Vitamin D
3
 (calcitriol) and its analogs calcipotriol and 
tacalcitol are well established in the therapy of psoriasis 
vulgaris due to their effects on epidermal differentiation 
and proliferation and regulation of production and release of 
proinflammatory cytokines.11 Most studies were done with 
calcipotriol and tacalcitol.36,37 Apparently, their effect on nail 
bed lesions is more marked than on matrix signs.
Calcineurin inhibitors have a profound inhibitory effect 
on T-cell functions that are implicated in the pathogenesis of 
psoriasis. Used systemically, cyclosporin A (CyA) is highly 
active against psoriasis, but topical application of CyA 
showed ambiguous results.11 The new calcineurin inhibitor 
tacrolimus shows much better skin and nail penetration. It 
demonstrated good activity on nail bed and matrix psoriasis 
in a controlled study.38 No studies with pimecrolimus were 
published until now.11
Tazarotene is a synthetic retinoid with antiinflammatory 
and antiproliferative actions on keratinocytes. Tazarotene 
0.1% was used for the treatment of nail psoriasis. The results 
were variable, but one study compared it with clobetasol 
showing equal results.25 It was also used in childhood nail 
psoriasis.39 Side effects are mainly skin irritation with redness 
and desquamation.11
5-Fluorouracil (5-FU) is an antimitotic and antiprolif-
erative agent, which is active against disorders with a high 
proliferative activity, such as psoriasis. Only one study of 
topical 5-FU with 20% urea as a penetration enhancer showed 
good effects on nail psoriasis, but inflammation, infection, 
onycholysis, and discoloration were observed as adverse 
effects.40 Other investigators did not see a beneficial response. 
This does not make 5-FU a favorite nail psoriasis agent.11
Dithranol was once the most commonly used antipso-
riatic topical, but because of its unpleasant cosmesis, it is 
rarely used nowadays. One study reported some improve-
ment of nail bed lesions, but the staining of the nails made 
it unacceptable.41
Indigo naturalis extract regulates proliferation and differ-
entiation of epidermal keratinocytes, restores the epidermal 
barrier function, and inhibits inflammatory reactions. Twice 
daily application of an oily extract reduced nail bed lesions 
such as hyperkeratosis and onycholysis by about one half; it 
was thus more effective than calcipotriol solution.42,43 Studies 
are in progress to make it colorless and cosmetically more 
acceptable (CH Yang, Chang Gung Memorial Hospital, per-
sonal communication, May 8, 2017).
Methotrexate was also used for perimatrical and nail bed 
injections with acceptable results. The dose was 0.1 mL of a 
25 mg/mL solution. Good results were seen after 6 months 
and 15 weeks, respectively.44,45
Systemic treatments are indicated in widespread psoria-
sis. Those therapies proven successful for skin lesions usu-
ally also improve nail psoriasis. However, many physicians 
and patients are reluctant to treat isolated ungual psoriasis 
systemically. A European Consensus Paper on the treatment 
of psoriasis defines the involvement of particularly sensi-
tive areas such as the head and neck, genito-anal area, and 
nails as moderate to severe. The selection of the mode of 
treatment then depends on the severity of the nail disease, 
its impact on quality of life, on professional, sports, and 
social activities, and in particular on potential associated 
psoriatic arthritis.
Systemic corticosteroids are not a good option for pso-
riasis vulgaris and in particular for nail psoriasis. High doses 
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are necessary with a considerable risk of serious side effects, 
break-through phenomena, and development of pustulation 
of hitherto not pustular psoriasis.
Methotrexate has been introduced into the treatment of 
cutaneous psoriasis and psoriatic arthritis in the 1960s. It is an 
inexpensive drug with good efficacy in skin lesions; however, 
as an antimetabolite, it slows down the nail growth rate and 
improvement in nail lesions is therefore often slow and seen 
very late (Figure 3). Furthermore, there is a risk of severe side 
effects such as hepatotoxicity, lymphopenia, lekopenia, nau-
sea, and erosive stomatitis. Long-term toxicity includes liver, 
lung, and heart fibrosis. The dose is usually slowly increased 
to reach ~10–20 mg/week. Both oral and injection therapies 
are possible with virtually equal doses as the bioavailability 
of methotrexate is very good.46–48 NAPSI improvement is 
between 25 and maximally 50%. Methotrexate has also been 
injected intralesionally with a good result.44,45
Ciclosporin A is another established systemic antipsori-
atic drug. It is a calcineurin inhibitor with strong immunosup-
pressive action. Its positive effect on cutaneous and ungual 
psoriasis is well established, both in single-drug studies as 
well as in comparative ones.49,50 The dose is usually 3–5 mg/
kg daily, but half the dose is often given in Japan after initial 
improvement.51 Although ciclosporin is probably the most 
active “classical” systemic antipsoriatic drug, it is limited 
to a treatment period of 6–12 months because of potentially 
serious adverse effects such as disturbance of renal function, 
arterial hypertension, diabetes mellitus, nausea, hypertricho-
sis, gingival hyperplasia, paresthesia, fatigue, and headache.
Synthetic retinoids have been used to treat extensive skin 
psoriasis. The first of these drugs was etretinate. Although it 
had a good effect on nail changes in some cases,52,53 etretinate 
is no longer used and substituted by its derivative acitretin.
Acitretin is the follower product of etretinate with a shorter 
half-life in the body. It is usually given in a dose of 0.5–1 mg/
kg/day.54,55 Its action is slow and, in most cases, does not reach 
>50% improvement of nail psoriasis.56 All retinoids have a 
number of side effects, particularly when given in a dose 
>0.5 mg/kg/day, such as dry and cracking lips, dry mouth, 
hair loss, and in children ossification disturbances. High-dose 
retinoids can have an onychodestructive effect and are no 
longer recommended as the first-line nail psoriasis treatment;57 
however, good results were seen in generalized pustular pso-
riasis and acrodermatitis continua suppurativa.57 Acitretin is 
occasionally used in combination with photochemotherapy 
with ultraviolet (UV) A and narrow band UV B.
Fumaric acid esters are used for psoriasis treatment in 
some countries, mainly in Europe, but their use was somewhat 
controversial. A case report described a good effect on nail 
psoriasis.58 Side effects are mainly gastrointestinal, flushing, 
lymphopenia, and rarely renal dysfunction.
Leflunomide is a disease-modifying antirheumatic agent 
with an effect on psoriatic arthritis and also a modest action 
on nail psoriasis.59 Sulfasalazine was used in one patient 
with a beneficial effect.60 Silicic acid was given orally and 
topically on skin lesions. Ten of the 12 patients treated had 
nail lesions, and five of them cleared completely, although 
the nails were not treated with the silicic acid gel; thus, a 
systemic effect was postulated.61
Apremilast is a new small-molecule oral phosphodies-
terase 4 inhibitor reducing the expression of several proin-
flammatory mediators; it is more an antiinflammatory than 
immunosuppressive agent distinguishing it from most other 
systemic antipsoriatic compounds. It has an excellent safety 
profile with no known organ toxicity, thus obviating the need 
for laboratory controls.62 It is approved for the treatment of 
cutaneous psoriasis and psoriatic arthritis and has shown a 
good effect in nail psoriasis, although only after 32 weeks. 
Its cost may, however, limit its widespread use.63,64 A nail 
lacquer containing apremilast is being developed;65 however, 
human studies on nail psoriasis have not yet been published.
Tofacitinib is a small-molecule oral Janus kinase inhibitor 
interfering in the JAK–STAT pathway. It is active against pso-
riasis and alopecia areata including their nail manifestations. 
In four Phase III randomized controlled studies and compared 
to etanercept, a twice daily dose of 5 or 10 mg was shown to 
be noninferior to etanercept injected subcutaneously twice 
weekly with sustained effects up to 52 weeks.66–69
Biologicals are a new development in the treatment of 
many, mainly immunologically mediated diseases, among 
them also psoriasis. There are several classes, both concern-
ing the nature of the antibody as well as their target, such 
as humanized and fully human antibodies and antibodies 
to tumor necrosis factor-a, various interleukins, and T-cell 
inhibitors, respectively. They all have profound immunosup-
pressive actions and are thus not without risk, particularly 
concerning infections and re-activation of tuberculosis, to 
mention but a few.11 Biologicals are usually considered sec-
ond- or third-line treatments when other established topical 
and systemic antipsoriatic drugs were not or not sufficiently 
active in suppressing nail lesions.70 In contrast, nail psoriasis 
was found to be an indicator of poor prognosis for the treat-
ment of psoriasis with biologicals independent of the specific 
substance used.71 In most cases, nail psoriasis responses lag 
behind those of cutaneous psoriasis, which can in part be 
explained by the slow growth of nails as nail plate changes 
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have to grow out, whereas nail bed changes may be seen 
earlier. In comparison with “classical” systemic drugs, eg, 
methotrexate and cyclosporin, biologicals often show a dra-
matic and more rapid improvement. However, only 20–57% 
of the patients reach a 90% improvement of their NAPSI 
score with biologicals and the effect is lost after 47 months 
in average.72,73 The most likely mechanism is the formation 
of antidrug antibodies, but compensatory production of 
other proinflammatory cytokines and a particular individual 
reaction may be the cause that many patients stop this treat-
ment.74 In many countries, biologicals are not automatically 
reimbursed by the social health insurance and patients and 
physicians have to give evidence that previous, less expensive 
treatments were not sufficiently efficacious.
TNF-a inhibitors were the first biologicals developed 
for psoriasis treatment. TNF-a is a cytokine with proinflam-
matory action that induces keratinocyte proliferation and 
prevents apoptosis. Most experience was gained with inflix-
imab, the first of this group, but in general, the efficacy of all 
TNF-a inhibitors currently available for psoriasis treatment 
is virtually comparable. Also their side effects and limita-
tions are the same. Activation of opportunistic infections, 
congestive heart failure, demyelinating disorder, antibodies 
against TNF-a inhibitors, and rarely lupus erythematosus 
may occur.11
Infliximab is a chimeric human-mouse IgG1 antibody 
binding membrane-bound and soluble TNF-a. This reduces 
epidermal T-lymphocyte infiltration. It exhibits certain anti-
genicity and may thus induce autoantibodies that may reduce 
its effectiveness thus requiring higher doses with time. It has 
to be given intravenously, and ~16% of the patients develop 
infusion reactions such as fever, chills, flush, urticaria, 
myalgia, arthralgia, nausea, hypotension, and dyspnea.75 
Infliximab was associated with a higher rate of onychomy-
cosis compared to the other TNF-a inhibitors.76 Patients 
with a high psoriasis area severity index (PASI) response 
also show a good NAPSI response. Almost one half of the 
patients demonstrated complete nail clearance after 50 weeks. 
NAPSI reduction by 50% was achieved by almost all patients, 
80% reached NAPSI-75, 30% reached NAPSI-90, and 10% 
cleared completely.77 Infliximab appears to be the fastest 
acting TNF-a inhibitor. Its dosage is usually 5 mg/kg given 
on weeks 0, 2, and 6 and if necessary 8.
Adalimumab is a human monoclonal IgG1 antibody 
against TNF-a. It binds to cell surface proteins of the TNF-a 
receptor preventing its action. Its mechanism of action is 
similar to that of infliximab. Roughly 50–60% of NAPSI 
improvement are achieved.11,78
The combination with cyclosporin was shown to be 
particularly effective reaching a reduction of the NAPSI 
score of 100%.79 Adalimumab did not increase the rate of 
onychomycoses.76 The dose is 80 mg at baseline, then 40 mg 
every 2 weeks, but some authors gave 40 mg from the begin-
ning (Figure 4).11
Certolizumab pegol is a PEGylated TNF-a inhibitor 
that is Fc free. It is effective in the treatment of rheumatoid 
arthritis and psoriasis with efficacy in nail psoriasis, enthesi-
tis, and dactylitis.80,81
Being a fusion of the TNF receptor with the Fc part of the 
IgG1 antibody etanercept blocks the action of TNF-a. Thus, 
its mechanism of action is similar to that of infliximab and 
adalimumab. Several reports on its use in nail psoriasis dem-
onstrated good results.82 There was no statistically different 
outcome with 50 mg once or twice weekly after 12 weeks and 
target NAPSI improvement between 71 and 76%.83 It was also 
effective in refractory acrodermatitis continua suppurativa.84
Golimumab is another TNF-a inhibitor approved for 
psoriatic arthritis with an effect on nail psoriasis. Target 
NAPSI improvement was over 40% after 24 weeks and 52% 
after 52 weeks of treatment with 50 mg every 4 weeks.85,86
All TNF-a inhibitors have the potential to paradoxically 
worsen psoriasis or even induce it.87,88 In many cases, this 
regresses despite continuation of the therapy or when another 
biological is used. This is apparently independent from the 
condition for which TNF-a inhibitors were administered.88–91 
The mechanism of action may be an unabated interferon-a 
production by plasmacytoid dendritic cells, which might result 
in psoriasis flares and induction of psoriasiform lesions.91,92
T-cell inhibitors such as alefacept and efalizumab are 
not widely used because of their considerable adverse effect 
profile.93 Efalizumab is a monoclonal CD11a antibody and 
was withdrawn from the market because of cases of leuken-
cephalopathy observed under treatment with this molecule. 
Alefacept is a fusion protein binding at the CD2 portion of 
the leukocyte function antigen-3 linked to the Fc portion of 
human IgG1 and targets T lymphocytes. No studies to evalu-
ate the efficacy of these drugs in nail psoriasis were published.
Rituximab causes B-cell depletion. Its role in the treat-
ment of nail psoriasis is not yet examined.93,94
New biologicals focus on the inhibition of interleukins 
involved in the propagation of the psoriatic process. Their 
nonspecific immunosuppressive action is less pronounced 
compared with the TNF-a inhibitors. The targets are mainly 
IL-12/IL-23 and IL-17. However, it was shown that anti-IL-12 
action might be proinflammatory under certain circumstances 
and thus counterproductive for the therapy of psoriasis.95
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Anti-interleukin 17 therapy is based on the fact that IL-17 
plays a central role in the development of psoriatic lesions, 
but IL-17 is also important for the defense against extracel-
lular pathogens and recruits neutrophils.
IL-17 inhibitors are secukinumab, ixekizumab, and bro-
dalimumab, but there are no ongoing studies with the last one.
Secukinumab is a human monoclonal IL-17A antibody 
approved for plaque psoriasis and psoriatic arthritis that has 
also shown good efficacy in nail psoriasis. It has an early 
onset action and a sustained effect. Its safety profile is accept-
able. It is administered subcutaneously with a 300 mg dose 
at weeks 0, 1, 2, 3, 4, and then every 4 weeks. At 16 weeks, 
both 150 and 300 mg secukinumab were superior to placebo 
with further improvement with longer treatment periods.96,97
Ixekizumab is another humanized monoclonal antibody 
directed against IL-17A recently approved for psoriasis. It 
demonstrated significant improvement of the NAPSI score as 
early as 2 weeks after start of the treatment, which sustained 
to week 20 when given in a dose of 75 mg at weeks 0, 2, 
4, 8, and 12 and then 120 mg every 4 weeks from week 20 
onward.98,99
Brodalumab is a human monoclonal IL-17A antibody 
active against plaque psoriasis. It was more active than 
ustekinumab in a head-to-head comparison. Although 
approved in the US and Japan, the clinical development was 
terminated as suicidal ideation and behavior were observed.100
IL-23 is another important proinflammatory cytokine 
involved in the pathogenesis of psoriasis.
Antibodies targeting the p40 subunit of IL-23 also have an 
action against IL-12 as they both share this subunit. Antibod-
ies directed against the p19 subunit are selective for IL-23.
Ustekinumab is a monoclonal antibody directed against 
the p40 subunit of IL-12/23. It is active against psoriasis and 
psoriatic arthritis and was also shown to have a good action 
on nail psoriasis. Nail improvement was observed from week 
4 onward with significant improvement of 90% at week 40. 
NAPSI and PASI improvement ran parallel. The dose is 45 
and 90 mg if the weight is over 100 kg, usually at weeks 0, 
4, 16, and 28.101–103 Efficacy and side effects are comparable 
to the other IL inhibitors.
Briakinumab was another monoclonal antibody directed 
at p40. After showing good clinical results, its development 
was stopped because of severe infections and a higher inci-
dence of other severe side effects.104
Guselkumab is a fully human IgG1k monoclonal IL-23 
antagonist directed against the unique p19 subunit of IL-23; 
it has no anti-IL-12 component. It has a profound action 
on moderate-to-severe plaque psoriasis and was superior to 
adalimumab.105 The dose given was 100 mg at weeks 0, 4, 
12, 16, and 20 and then every 8 weeks.
Tildrakizumab and BI-655066 are also targeting the p19 
subunit of IL-23. They are currently being studied for vari-
ous indications including psoriasis.106,107 No results are yet 
available concerning nail psoriasis.
In summary, most new biological drugs have a good and 
reliable action on nail psoriasis with an acceptable adverse 
effect profile. They are more active than most of the classical 
systemic antipsoriatic drugs.
Radiotherapy is an “old“ treatment modality, which has 
come out of time not only because of potential long-term 
adverse effects but also because most dermatologists no 
longer operate X-ray machines because of the difficulties to 
comply with the bureaucratic challenges associated with the 
use of therapeutic ionizing rays. However, some studies report 
favorable results with Grenz rays,108 superficial X-rays,109,110 
and electron beam therapy.111
Light has been used for a long time, but as nails are 
virtually impermeable for UV B and allow <2% of UV A to 
penetrate, the effect is rather limited.112 Potentiation of UV 
by specific photosensitizers, called photochemotherapy, was 
beneficial in some studies48,113 but is often associated with 
multiple melanonychias.114
Intense pulsed light (IPL) is a broad-spectrum light 
source with a high-energy intensity. With a 550 nm filter, it 
has been used for the treatment of plaque psoriasis. A trial 
on 20 patients with finger and toenail psoriasis using IPL 
with a cutoff filter of 550 nm and a median of 8.6 sessions 
resulted in significant improvement in the NAPSI with 
nail bed lesions showing a reduction of 71% and matrix 
lesions of 32%. A relapse was seen in three patients after 
6 months.115
Lasers have also been used to treat nail psoriasis. The 
pulsed dye laser (PDL) is the device of choice as it targets 
the dilated capillaries in the matrix and nail bed. In many 
studies, 1.5–6 ms pulses were used with a good effect on 
matrix and nail bed lesions.116,117 A comparative study using 
6 ms pulse length and 9 J/cm2 and 0.45 ms and 6 J/cm2 
gave almost the same improvement of matrix and nail bed 
lesions with significantly less pain with the shorter pulse.118 
Side effects are mainly pain, hemorrhage, and pigmentation. 
These results were confirmed in another trial.119 PDL with 
tazarotene was significantly more effective than tazarotene 
alone.120 A comparison of the PDL with the excimer laser 
gave significantly better improvement with the PDL.121 In 
another comparative study, PDL was compared with the 
Nd:YAG laser. Both groups were treated with calcipotriol 
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betamethasone in addition. Whereas the results were com-
parably good, the Nd–YAG was significantly more painful.122
Photodynamic therapy (PDT) uses light and a photoactive 
substance that both generate reactive oxygen species able 
to kill those cells that accumulated the photosensitizer. In a 
comparative study, no difference was found between PDL 
and PDT.117 However, there is considerable heat develop-
ment during the illumination of the target and this is often 
not tolerated by the patients.
Conclusion
Nail involvement in psoriasis is common. It is an indicator of 
poor prognosis and of a higher risk to develop psoriatic arthritis. 
Surprisingly, nail psoriasis is only briefly mentioned in most 
national and European guidelines on the diagnosis and treat-
ment of psoriasis; however, the European Nail Society is now 
working on recommendations for the treatment of nail psoriasis.
The many treatments available give evidence that hitherto 
none is the ideal therapy. Topicals have to fight with the dif-
ficulties to get through the nail and nail fold to the diseased 
structures. Injections that bring the remedy to the site of the 
disease process and greatly avoid systemic effects are pain-
ful and carry the risk of local side effects. Systemic drugs 
are often not used for isolated nail psoriasis, although this is 
accepted as a severe psoriasis considerably impairing quality 
of life. However, it is known that virtually all systemic treat-
ments that improve the skin lesions are also beneficial for 
the nails, although often with a delayed and less pronounced 
response. The potential systemic adverse effects have to be 
kept in mind before and during such a therapy. The develop-
ment of new biologicals has revolutionized psoriasis treat-
ment and thus also that of ungual psoriasis. Finally, there 
are some physical modalities such as ionizing rays, various 
light qualities including photodynamic treatment, and lasers.
Many treatment possibilities may make it delicate to 
choose the right approach. It is certainly wise to begin with 
a topical antipsoriatic preparation (Table 2). This has to be 
used for a minimum of 4–6 months before its efficacy can 
be evaluated. If this does not help sufficiently, a classical 
antipsoriatic drug such as methotrexate, fumaric acid ester, 
and cyclosporine would be the second choice while keep-
ing in mind all potential contraindications. If the results are 
not satisfying a biological may be chosen. Again, there are 
many contraindications that have to be carefully looked for 
before starting such a treatment. The choice is huge now, and 
the treating physician has to select among TNF-a blockers, 
agents interfering with T-lymphocyte functions, and IL-23 
and IL-17 inhibitors.
In summary, nail psoriasis is still an underestimated part 
of psoriasis, but the outlook is bright with many new treat-
ments available.
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